OBJECTIVES: The aim of our work was to evaluate the role of nitric oxide (NO) in the in vitro response of human gingival fibroblasts (HGFs) to 1, 5, 10, and 100 μM doses of zoledronic acid (ZA), a bisphosphonate largely used in the clinical practice and for which several adverse effects are reported. MATERIALS AND METHODS: Phase contrast microscopy and live/dead staining were used to evaluate HGFs morphology; cell viability, collagen type I and interleukin 6 (IL-6) secretion were evaluated by 3-[4,5-dimethyl-thiazol-2-yl-]-2,5-diphenyl tetrazolium bromide (MTT) and enzyme-linked immunosorbent assay (ELISA) assays. Reactive oxygen species (ROS) production and mitochondrial membrane potential were evaluated by flow cytometry; NO production and NOS activity by spectrophotometric analysis; endothelial NOS (eNOS) and neuronal NOS (nNOS) expression by immunofluorescence. RESULTS: Viable fibroblasts are evidenced in control sample while floating dead cells and cells close to detachment phase in ZA-treated sample, in agreement with decreased level of collagen type I. Control sample shows higher number of viable cells respect to ZA-treated one and ROS production increases when ZA is added. Released NO in ZA-treated sample appears higher and NO overproduction is related to increased nNOS activity. IL-6 secretion level is higher in ZA-treated sample than in control one. CONCLUSIONS: Our results suggest ROS involvement in NO overproduction, due to nNOS recruitment, both at low and high doses. In turn, NO release seems to be able to trigger the inflammatory response only when high doses are administered, thus confirming the ZA cytotoxic effect on HGFs. CLINICAL RELEVANCE: The knowledge of ZA-mediated cytotoxicity mechanisms on HGFs allows to better understand drug pharmacological activity.
OBJECTIVES: The aim of our work was to evaluate the role of nitric oxide (NO) in the in vitro response of human gingival fibroblasts (HGFs) to 1, 5, 10, and 100 μM doses of zoledronic acid (ZA), a bisphosphonate largely used in the clinical practice and for which several adverse effects are reported. MATERIALS AND METHODS: Phase contrast microscopy and live/dead staining were used to evaluate HGFs morphology; cell viability, collagen type I and interleukin 6 (IL-6) secretion were evaluated by 3-[4,5-dimethyl-thiazol-2-yl-]-2,5-diphenyl tetrazolium bromide (MTT) and enzyme-linked immunosorbent assay (ELISA) assays. Reactive oxygen species (ROS) production and mitochondrial membrane potential were evaluated by flow cytometry; NO production and NOS activity by spectrophotometric analysis; endothelial NOS (eNOS) and neuronal NOS (nNOS) expression by immunofluorescence. RESULTS: Viable fibroblasts are evidenced in control sample while floating dead cells and cells close to detachment phase in ZA-treated sample, in agreement with decreased level of collagen type I. Control sample shows higher number of viable cells respect to ZA-treated one and ROS production increases when ZA is added. Released NO in ZA-treated sample appears higher and NO overproduction is related to increased nNOS activity. IL-6 secretion level is higher in ZA-treated sample than in control one. CONCLUSIONS: Our results suggest ROS involvement in NO overproduction, due to nNOS recruitment, both at low and high doses. In turn, NO release seems to be able to trigger the inflammatory response only when high doses are administered, thus confirming the ZA cytotoxic effect on HGFs. CLINICAL RELEVANCE: The knowledge of ZA-mediated cytotoxicity mechanisms on HGFs allows to better understand drug pharmacological activity.
Authors: Jose V Bagan; Yolanda Jimenez; Judith Murillo; Sergio Hernandez; Rafael Poveda; José M Sanchis; José M Diaz; Crispian Scully Journal: Oral Oncol Date: 2005-11-04 Impact factor: 5.337
Authors: Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan Journal: J Oral Maxillofac Surg Date: 2011-07-31 Impact factor: 1.895
Authors: Y Açil; B Möller; P Niehoff; K Rachko; V Gassling; J Wiltfang; M J K Simon Journal: J Craniomaxillofac Surg Date: 2011-11-13 Impact factor: 2.078
Authors: S Defrère; J C Lousse; R González-Ramos; S Colette; J Donnez; A Van Langendonckt Journal: Mol Hum Reprod Date: 2008-05-28 Impact factor: 4.025
Authors: Ji Suk Shim; Dong-Sik Park; Dong-Heon Baek; Nayansi Jha; Serk In Park; Hyoung Jin Yun; Won Jong Kim; Jae Jun Ryu Journal: PLoS One Date: 2018-10-04 Impact factor: 3.240
Authors: Francesca Diomede; Guya Diletta Marconi; Simone Guarnieri; Michele D'Attilio; Marcos F X B Cavalcanti; Maria A Mariggiò; Jacopo Pizzicannella; Oriana Trubiani Journal: Materials (Basel) Date: 2019-12-27 Impact factor: 3.623
Authors: Anna Di Vito; E Chiarella; F Baudi; P Scardamaglia; A Antonelli; D Giudice; T Barni; L Fortunato; A Giudice Journal: Cell Transplant Date: 2020 Jan-Dec Impact factor: 4.064